Leqembi (Lecanemab-Irmb) Patent Expiration, LOE Window & CMS Spending

Leqembi (Lecanemab-Irmb) by Eisai: Biologic BLA (Purple Book Regime), 0 AB generics, $947K 2024 CMS Part D & Medicaid spend, and $770 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEisai
FDA Application & PathwayB761269 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$947K
2024 Medicare Part D Spend$514K
2024 Medicaid Spend$433K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($770 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eisai across sibling Meru public-data platforms.